Lior Raviv
Chief Tech/Sci/R&D Officer at PLURI INC.
Lior Raviv active positions
Companies | Position | Start | End |
---|---|---|---|
PLURI INC. | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 2010-12-31 | - |
Career history of Lior Raviv
Former positions of Lior Raviv
Companies | Position | Start | End |
---|---|---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 2010-06-30 | 2011-01-31 |
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Chief Operating Officer | - | - |
Training of Lior Raviv
Ben-Gurion University of the Negev | Undergraduate Degree |
Statistics
International
Israel | 5 |
Operational
Chief Operating Officer | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
PLURI INC. | Health Technology |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
Private companies | 1 |
---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
- Stock Market
- Insiders
- Lior Raviv
- Experience